An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy | Journal for ImmunoTherapy of Cancer (bmj.com)
Review: N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer?
""future clinical trials for cancers or infectious diseases should not use mRNA vaccines with a 100 % m1Ψ modification, but rather ones with the lower percentage of m1Ψ modification to avoid immune suppression."
mORE HUMAN EXPERIMENTATION NEEDED TO DETERMINE THE OPTIMAL LEVEL OF m1Ψ
Hi Peter, yes, IgG4 shift is big yet overlooked by regulators? Doubt it. Cancer is a huge industry with profits through the roof. Too much money and future fame may be involved. Did you happen to see this? "WHO: Intel Agency for Gates Foundation?
Given the turbo cancers are obviously related to cv injections, wouldn't it make sense to inject the mice with the various known and suspected ingredients of the vaccines, one by one, and identify which of the toxins lead to proliferation of IgG4, rather than injecting them directly with cancer cells?
Yes. Sunds like resarch is just beginning. This research was investigating cancer not mRNA injections with all their contaminants and adulterated contents.
Hopefully this sort of work inspires others to investigate whether there is merit in using IGg1 to not only "stalk up" with cancer inducing IGg4, but also how it reacts with cancer risks form SV40, peg, endotoxins, e-coli, pseudo-uridine et al.
Looks like IgG4 is the smoking gun of turbo cancers. With the vaccine induced IgG4 cells and the bacterial plasmid DNA in the vials…it is amazing that vaccinated folks don’t all get some form of cancer at some point.
h/t Jayne dOE:
"Friend or Foe Cancer" paper author's recent work as well - https://www.sciencedirect.com/science/article/abs/pii/S0141813024022323
Review: N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer?
""future clinical trials for cancers or infectious diseases should not use mRNA vaccines with a 100 % m1Ψ modification, but rather ones with the lower percentage of m1Ψ modification to avoid immune suppression."
mORE HUMAN EXPERIMENTATION NEEDED TO DETERMINE THE OPTIMAL LEVEL OF m1Ψ
Hi Peter, yes, IgG4 shift is big yet overlooked by regulators? Doubt it. Cancer is a huge industry with profits through the roof. Too much money and future fame may be involved. Did you happen to see this? "WHO: Intel Agency for Gates Foundation?
Examining the Foundation's prescient Aug. 2019 purchase of BioNTech stock." - - https://petermcculloughmd.substack.com/p/who-intel-agency-for-gates-foundation
https://www.bing.com/images/search?view=detailV2&ccid=51gXSqig&id=781AA344976C4044032F5988E1F5FE69CABEB4D1&thid=OIP.51gXSqigbV5h-f57CACp4QAAAA&mediaurl=https%3a%2f%2fwww.ctvnews.ca%2fpolopoly_fs%2f1.1883033.1403576701!%2fhttpImage%2fimage.jpg_gen%2fderivatives%2flandscape_225%2fimage.jpg&cdnurl=https%3a%2f%2fth.bing.com%2fth%2fid%2fR.e758174aa8a06d5e61f9fe7b0800a9e1%3frik%3d0bS%252bymn%252b9eGIWQ%26pid%3dImgRaw%26r%3d0&exph=127&expw=225&q=bOB+mARTIN+VACCINE+INJURED&simid=608048339116971674&FORM=IRPRST&ck=EB8B03D143EE3299C786D2ADFD37FAA1&selectedIndex=0&itb=0
Given the turbo cancers are obviously related to cv injections, wouldn't it make sense to inject the mice with the various known and suspected ingredients of the vaccines, one by one, and identify which of the toxins lead to proliferation of IgG4, rather than injecting them directly with cancer cells?
Yes. Sunds like resarch is just beginning. This research was investigating cancer not mRNA injections with all their contaminants and adulterated contents.
https://www.nature.com/articles/s41577-023-00E871-z
Hopefully this sort of work inspires others to investigate whether there is merit in using IGg1 to not only "stalk up" with cancer inducing IGg4, but also how it reacts with cancer risks form SV40, peg, endotoxins, e-coli, pseudo-uridine et al.
Looks like IgG4 is the smoking gun of turbo cancers. With the vaccine induced IgG4 cells and the bacterial plasmid DNA in the vials…it is amazing that vaccinated folks don’t all get some form of cancer at some point.